pazopanib

pazopanib

美 　英

• 網絡帕唑帕尼；鹽酸帕唑帕尼；帕唑帕尼片

例句

The preclinical and clinical researches have demonstrated that pazopanib has potent antitumor effects and is well tolerated.

該藥在臨床前和臨床研究中表現出了較強的抗腫瘤活性，且耐受性較好。

Pazopanib was evaluated in a placebo-controlled Phase 3 study involving 435 patients with renal cell carcinoma.

帕唑帕尼進行了評估，安慰劑控制的第三期涉及435例腎細胞癌患者的研究。

Patients were randomized (2: 1) to receive pazopanib 800mg or placebo once daily.

患者被隨機（2：1）接受800毫克或安慰劑帕唑帕尼每日一次。

In this trial, the overall median progression free survival (PFS) was 9. 2 months with pazopanib and 4. 2 months with placebo.

在這個試驗中，整體無進展生存期（PFS）為9.2和4.2個月，帕唑帕尼與安慰劑個月。

Treatment-naive patients who received pazopanib experienced 11. 1 months of median PFS vs 2. 8 months with placebo.

治療初治患者誰收到帕唑帕尼經驗的中位PFS11.1個月比2.8個月的安慰劑。